Johnson & Johnson (J&J) has secured a CE mark in Europe for its Varipulse pulsed field ablation (PFA) device, marking a significant step in the treatment of atrial fibrillation (AFib). This approval positions J&J to compete with Medtronic and Boston Scientific in this promising new technology for managing this common heart rhythm disorder. AFib is a condition where the upper chambers of the heart beat irregularly and out of sync with the lower chambers. This irregularity can increase the risk of stroke and other cardiovascular complications.
Atrial fibrillation is a common heart rhythm disorder where the upper chambers of the heart beat irregularly and out of sync with the lower chambers. This irregularity can lead to several complications, most notably an increased risk of stroke. Traditionally, treating AFib has involved a procedure called catheter ablation. During this procedure, a thin tube is inserted into the heart and used to deliver heat energy to destroy the faulty tissue causing the abnormal rhythm.
However, this approach using heat, known as thermal ablation, carries its own set of risks. The heat energy can potentially damage surrounding healthy tissue, such as the esophagus or pulmonary vein. This is where a new and promising technology called pulsed field ablation comes in.
Johnson & Johnson’s Varipulse Leads with Pulsed Field Ablation Innovation for AFib Treatment
Unlike thermal ablation, pulsed field ablation utilizes short, high-intensity electrical pulses delivered through a catheter to target and disrupt the cell membranes of the faulty heart tissue. This disruption, known as irreversible electroporation, essentially renders the targeted cells non-functional, effectively stopping them from contributing to the abnormal heart rhythm. One of the key advantages of pulsed field ablation lies in its ability to deliver a more targeted treatment. By using electrical pulses instead of heat, pulsed field ablation minimizes the risk of damaging surrounding healthy tissues. This is particularly important when treating areas near sensitive structures like the esophagus and pulmonary vein.
Since PFA avoids the use of heat, it eliminates the potential for complications associated with thermal damage, such as burns or scarring. This could potentially lead to a safer overall procedure for patients with AFib. PFA technology offers the potential for a more precise approach to ablation. The electrical pulses can be tailored to target specific areas of faulty tissue, potentially leading to improved outcomes and reduced need for repeat procedures.
Johnson & Johnson’s Varipulse device recently received CE mark approval in Europe for treating AFib. This approval signifies a significant step forward for pulsed field ablation technology and positions J&J to compete with established players like Medtronic and Boston Scientific, who already have pulsed field ablation systems in use within Europe and recently secured FDA approval for their devices in the U.S.
The positive results from J&J’s Inspire clinical trial, involving over 180 patients, further bolster the potential of PFA. Early data suggests that a significant portion of patients receiving optimal PFA treatment with the Varipulse device achieved freedom from AFib recurrence after one year.
Johnson & Johnson’s Varipulse Sparks Growth and Innovation in PFA Technology
J&J’s entry into the PFA market with the Varipulse device intensifies the competition in this space. The promising results from clinical trials suggest that PFA has the potential to become a valuable tool for managing AFib. As J&J seeks FDA approval in the U.S. and other companies continue to refine their PFA technologies, we can expect further advancements and wider adoption of PFA in the coming years. This could lead to safer, more effective treatment options for millions of patients suffering from AFib. J&J’s Varipulse device received CE mark approval in Europe for treating AFib. This approval allows J&J to compete with established players like Medtronic and Boston Scientific in the PFA market.
The Inspire clinical trial involving 186 patients in Canada and Europe demonstrated the safety and effectiveness of the Varipulse platform. Early results from the Inspire trial showed promising outcomes, with 80% of patients receiving optimal PFA treatment achieving freedom from AFib recurrence after one year. J&J plans to submit the Varipulse catheter for FDA approval in the United States this year.
PFA offers a potentially safer and more precise approach compared to traditional thermal ablation techniques. By using electrical pulses, pulsed field ablation minimizes the risk of collateral damage to surrounding tissues like the esophagus and pulmonary vein. Medtronic and Boston Scientific already have pulsed field ablation systems in use within Europe. Both companies have also received FDA approval for their pulsed field ablation devices in the U.S.
J&J’s entry into the PFA market with the Varipulse device intensifies the competition in this space. The positive results from the Inspire trial suggest the potential of pulsed field ablation as a valuable tool for managing AFib. As J&J seeks FDA approval in the U.S., the coming years will likely see further advancements and wider adoption of PFA technology for treating AFib patients.
Resource: Med Tech Dive, February 29, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
